Total mortality · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total mortality compared with standard blood pressure targets (moderate certainty).
1 finding from 1 review
Total mortality · adults with primary hypertension
1 finding from 1 review
Mortality: lung cancer · healthy adults
Low‐dose computed tomography (LDCT) screening probably leads to lower lung cancer‐related mortality ‐ planned time points compared with no LDCT screening (moderate certainty).
1 finding from 1 review
Perinatal mortality · pregnant women
1 finding from 1 review
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Lower total dose radiotherapy (67.2 Gy over 5.6 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 1.38 [0.83, 2.29]
1 study
GRADE not reported
All‐cause mortality · Patients with lung cancer
Annual low‐dose CT screening showed no clear difference in all‐cause mortality compared with annual chest x‐ray (high certainty).
1 finding from 1 review
Total mortality · Adults with oral cavity or oropharyngeal cancer with nodal disease (stage N2 or N3)
PET-CT following chemoradiotherapy (neck dissection only if… showed no clear difference in total mortality compared with planned neck dissection before or after chemoradiotherapy (moderate certainty).
1 finding from 1 review
All‐cause mortality ( · adults undergoing KA
1 finding from 1 review
Mortality: lung cancer · Patients with lung cancer
Annual low‐dose CT screening leads to lower lung cancer mortality compared with annual chest x‐ray (high certainty).
1 finding from 1 review
Perinatal mortality · pregnant women with GDM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).
1 finding from 1 review
Mortality or morbidity composite · pregnant women
1 finding from 1 review
Mortality before hospital discharge · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes mortality, by hospital discharge compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
2 findings from 1 review
Mortality ‐ Death at any time after surgery · adult cardiac surgical patients
Low‐dose opioid‐based GA showed no clear difference in mortality ‐ Death at any time after surgery compared with high‐dose opioid‐based GA (low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review